The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 101–200 of 1,000
Takahashi, M., Kuroki, Y., Ohtsubo, K., & Taniguchi, N. (2009) · Carbohydrate Research · doi:10.1016/j.carres.2009.04.031 · Cited by 223
Production of human monoclonal antibody in eggs of chimeric chickens
Zhu, L., van de Lavoir, M.-C., Albanese, J., Beenhouwer, D. O., Cardarelli, P. M., Cuison, S., Deng, D. F., Deshpande, S., Diamond, J. H., Green, L., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1132 · Cited by 222
Peschke, B., Keller, C. W., Weber, P., Quast, I., & Lünemann, J. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00646 · Cited by 219
“FcγRIIIa binding was strongest for IgG1 and IgG3 isotypes FigUre 3 | Increased CDC of rituximab-derived immunoglobulin gamma 1 (IgG1) and IgG3 but not IgG2 and IgG4 upon Fc-galactosylation.”
BackgroundInfluentialIn vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity
Thomann, M., Schlothauer, T., Dashivets, T., Malik, S., Avenal, C., Bulau, P., Rüger, P., & Reusch, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134949 · Cited by 220
Lectin-resistant CHO glycosylation mutants
Patnaik, S. K., & Stanley, P. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(06)16011-5 · Cited by 218
Unverzagt, C., & Kajihara, Y. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35485g · Cited by 218
Mimura, Y., Katoh, T., Saldova, R., O’Flaherty, R., Izumi, T., Mimura-Kimura, Y., Utsunomiya, T., Mizukami, Y., Yamamoto, K., Matsumoto, T., et al. (2018) · Protein & Cell · doi:10.1007/s13238-017-0433-3 · Cited by 217
“The BioWa (or Kyowa Hakko Kirin) group produced an anti-CD20 antibody with low fucose contents (9%) in rat YB2/0 B-lymphoblast cells, and the antibody exhibited enhanced ADCC using human peripheral blood mononuclear cells (Shinkawa et al., 2003).”
BackgroundInfluentialZhang, P., Woen, S., Wang, T., Liau, B., Zhao, S., Chen, C., Yang, Y., Song, Z., Wormald, M. R., Yu, C., et al. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.006 · Cited by 213
Riether, C., Pabst, T., Höpner, S., Bacher, U., Hinterbrandner, M., Banz, Y., Müller, R., Manz, M. G., Gharib, W. H., Francisco, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0910-8 · Cited by 207
Iida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206
Self-citationInduction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
Takeda, K., Yamaguchi, N., Akiba, H., Kojima, Y., Hayakawa, Y., Tanner, J. E., Sayers, T. J., Seki, N., Okumura, K., Yagita, H., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031457 · Cited by 206
“Moreover, mAbs are quite amenable to engineering to improve their half-life (by humanization; 56–58), their agonistic activity by modification of the antigen-binding portion or the Fc portion (56, 58), and their ADCC by defucosylation (59).”
BackgroundYamaguchi, Y., Nishimura, M., Nagano, M., Yagi, H., Sasakawa, H., Uchida, K., Shitara, K., & Kato, K. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.10.002 · Cited by 204
Self-citationYu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203
“A major focus has been on the study of afucosylated antibodies whose Fc N-linked glycans lack core fucose, which results in an up to 50-fold increase in ADCC activity.(8,11) Different methods to generate the complex type afucosylated (AF) glycoform have been investigated, including cell line engineering, knockout/ kno…”
BackgroundAnti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy
Wang, T. T., Maamary, J., Tan, G. S., Bournazos, S., Davis, C. W., Krammer, F., Schlesinger, S. J., Palese, P., Ahmed, R., & Ravetch, J. V. (2015) · Cell · doi:10.1016/j.cell.2015.06.026 · Cited by 201
“, 1999) (Shinkawa et al., 2003).”
InfluentialA common glycan structure on immunoglobulin G for enhancement of effector functions
Lin, C.-W., Tsai, M.-H., Li, S.-T., Tsai, T.-I., Chu, K.-C., Liu, Y.-C., Lai, M.-Y., Wu, C.-Y., Tseng, Y.-C., Shivatare, S. S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513456112 · Cited by 200
“Toward this goal, it has been reported that removal of the core fucose residue enhances the antibody-dependent cellular cytotoxicity (ADCC) activity of immunoglobulin Gs (IgGs) (5, 6) due to the increased Fc-glycan interaction with FcγRIIIa receptor (5, 7, 8).”
BackgroundHarris, R. J., Shire, S. J., & Winter, C. (2004) · Drug Development Research · doi:10.1002/ddr.10344 · Cited by 198
“Terminal galactose levels correlate with complement-mediated cell killing in vitro [Tsuchiya et al., 1989], while core fucosylation inversely correlates with antibody-dependent cellular cytoxicity (ADCC) [Shields et al., 2002; Shinkawa et al., 2003].”
BackgroundMultiplexed Fc array for evaluation of antigen-specific antibody effector profiles
Brown, E. P., Dowell, K. G., Boesch, A. W., Normandin, E., Mahan, A. E., Chu, T., Barouch, D. H., Bailey-Kellogg, C., Alter, G., & Ackerman, M. E. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.01.010 · Cited by 195
“The PCA analysis function prcomp was used for generating lead PCs.”
Ronda, C., Pedersen, L. E., Hansen, H. G., Kallehauge, T. B., Betenbaugh, M. J., Nielsen, A. T., & Kildegaard, H. F. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25233 · Cited by 195
“The a1,6-fucosyltransferase FUT8 catalyzes the addition of fucose on IgG1 antibodies produced by CHO cells which can reduce antibody-dependent cell-mediated cytotoxicity (Niwa et al., 2004; Shields et al., 2002; Shinkawa et al., 2003).”
BackgroundThe history of IgG glycosylation and where we are now
Cobb, B. A. (2020) · Glycobiology · doi:10.1093/glycob/cwz065 · Cited by 193
“The initial discovery was the demonstration that IgG molecules lacking fucose had enhanced ADCC via increased FcγRIIIA binding and signaling (Okazaki et al. 2004; Shields et al. 2002; Shinkawa et al. 2003).”
BackgroundModulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose
Gramer, M. J., Eckblad, J. J., Donahue, R., Brown, J., Shultz, C., Vickerman, K., Priem, P., van den Bremer, E. T. J., Gerritsen, J., & van Berkel, P. H. C. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23075 · Cited by 193
“…to: M. J. Gramer 2011 Wiley Periodicals, Inc. Biotechnology and Bioengineering, Vol. 108, No. 7, July, 2011 1591 impact ADCC (Shields et al., 2002; Shinkawa et al., 2003; Peipp et al., 2008), galactose levels may impact CDC (Boyd et al., 1995; Hodoniczky et al., 2005; Tsuchiya et al., 1989;…”
Novel roles for the IgG Fc glycan
Anthony, R. M., Wermeling, F., & Ravetch, J. V. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06305.x · Cited by 186
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 187
Self-citationNiwa, R., Sakurada, M., Kobayashi, Y., Uehara, A., Matsushima, K., Ueda, R., Nakamura, K., & Shitara, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2263 · Cited by 187
“7B); accordingly, CD56/CD69 expression levels in NK cells mixed with target cells for 4 and 24 hours were analyzed in the absence or presence of various antibodies (KM3065, rituximab, or anti-CCR4 KM2760 as an irrelevant control antibody; Fig.”
BackgroundSelf-citationWada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
Antibody glycosylation in inflammation, disease and vaccination
Alter, G., Ottenhoff, T. H. M., & Joosten, S. A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.003 · Cited by 186
“Conversely, removal of fucose has a profound impact on modulating FcγR3a binding [39], through a glycan:glycan interaction with a second fucose attached to the Fc-receptor [53].”
BackgroundZhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie‐Wylie, A., Culm‐Merdek, K., Park, A., Pan, C., & Edmunds, T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21598 · Cited by 184
Mechanisms of disease: The human N-glycome
Lauc, G., Pezer, M., Rudan, I., & Campbell, H. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.10.016 · Cited by 184
“By contrast, ADCC induced by non-fucosylated IgG seems to be one of the primary modes of function of therapeutic anticancer monoclonal antibodies, since IgG molecules lacking core-fucose are over 100 timesmore effective in initiatingADCC [45,49,50].”
BackgroundHolland, M., Yagi, H., Takahashi, N., Kato, K., Savage, C. O. S., Goodall, D. M., & Jefferis, R. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.11.021 · Cited by 184
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Marshall, M. J. E., Stopforth, R. J., & Cragg, M. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01245 · Cited by 183
“confirmed this and reported increased ADCC using low fucose anti-CD20 mAb (139).”
Ishida, T., Inagaki, H., Utsunomiya, A., Takatsuka, Y., Komatsu, H., Iida, S., Takeuchi, G., Eimoto, T., Nakamura, S., & Ueda, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0371 · Cited by 180
“This chimeric MoAb has a Fc region that is artificially defucosylated to enhance antibody-dependent cellular cytotoxicity activity by increasing its binding affinity to Fc R on effector cells (25, 35).”
BackgroundFc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies
Thomann, M., Reckermann, K., Reusch, D., Prasser, J., & Tejada, M. L. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.03.002 · Cited by 179
Masuda, K., Kubota, T., Kaneko, E., Iida, S., Wakitani, M., Kobayashi-Natsume, Y., Kubota, A., Shitara, K., & Nakamura, K. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.02.005 · Cited by 179
Self-citationSeeling, M., Brückner, C., & Nimmerjahn, F. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.146 · Cited by 179
Guidelines to cell engineering for monoclonal antibody production
Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.10.002 · Cited by 178
“The overexpression of Nacetylglucosaminyltransferase III (GNTIII) can be achieved by transfecting cells with the GNTIII enzyme and results in nonfucosylated mAbs that have improved ADCC and CDC functions [184,189,190].”
BackgroundNon-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Satoh, M., Iida, S., & Shitara, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1161 · Cited by 175
“Among these efforts, the modification of N-linked oligosaccharides attached to the Fc region of the antibody has been of note [41-48,201,202].”
BackgroundMethodInfluentialSelf-citationMori, K., Kuni‐Kamochi, R., Yamane‐Ohnuki, N., Wakitani, M., Yamano, K., Imai, H., Kanda, Y., Niwa, R., Iida, S., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20326 · Cited by 174
Self-citationIn vitro and in vivo modifications of recombinant and human IgG antibodies
Liu, H., Ponniah, G., Zhang, H.-M., Nowak, C., Neill, A., Gonzalez-Lopez, N., Patel, R., Cheng, G., Kita, A. Z., & Andrien, B. (2014) · mAbs · doi:10.4161/mabs.29883 · Cited by 168
Butler, M. (2006) · Cytotechnology · doi:10.1007/s10616-005-4537-x · Cited by 171
“The presence of a bisecting N-acetylglucosamine (Umana et al. 1999; Davies et al. 2001) or the absence of fucose (Shields et al. 2002; Shinkawa et al. 2003; Okazaki et al. 2004) in the conserved glycan of an IgG antibody has been shown to enhance attachment to Fc receptors and result in an increase…”
BackgroundProduction of therapeutic antibodies with controlled fucosylation
Yamane-Ohnuki, N., & Satoh, M. (2009) · mAbs · doi:10.4161/mabs.1.3.8328 · Cited by 170
Self-citationCurrent and future issues in the manufacturing and development of monoclonal antibodies
Kozlowski, S., & Swann, P. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.002 · Cited by 170
The Ligands for Human IgG and Their Effector Functions
de Taeye, S. W., Rispens, T., & Vidarsson, G. (2019) · Antibodies · doi:10.3390/antib8020030 · Cited by 170
“Although not commonly found in plasma, afucosylated glycan-species of the N297 glycan (found in ~6% of plasma IgG) were previously found to increase the binding strength of IgG-Fc to FcγRIIIa [81,103,104].”
BackgroundRole of Protein Glycosylation in Host-Pathogen Interaction
Lin, B., Qing, X., Liao, J., & Zhuo, K. (2020) · Cells · doi:10.3390/cells9041022 · Cited by 169
Reusch, D., Haberger, M., Maier, B., Maier, M., Kloseck, R., Zimmermann, B., Hook, M., Szabo, Z., Tep, S., Wegstein, J., et al. (2015) · mAbs · doi:10.4161/19420862.2014.986000 · Cited by 168
“Afucosylation (lack of core fucose) promotes antibodydependent cellular cytotoxicity (ADCC) by increased binding of the IgG Fc portion to FcgRIIIa on natural killer cells.(12,13) Glycoforms can also affect pharmacodynamics and pharmacokinetics.”
Inflammatory Bowel Disease Associates with Proinflammatory Potential of the Immunoglobulin G Glycome
Trbojević Akmačić, I., Ventham, N. T., Theodoratou, E., Vučković, F., Kennedy, N. A., Krištić, J., Nimmo, E. R., Kalla, R., Drummond, H., Štambuk, J., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000372 · Cited by 166
Antibody Engineering for the Development of Therapeutic Antibodies
Kim, S. J., Park, Y., & Hong, H. J. (2005) · Molecules and Cells · doi:10.1016/s1016-8478(23)25245-0 · Cited by 167
“Recently, it was reported that elimination of the fucose moiety from the core of the Fc N-linked glycan profoundly improved binding to FcγRs and the ADCC activity (Shields et al., 2002; Shinkawa et al., 2003).”
BackgroundZou, G., Ochiai, H., Huang, W., Yang, Q., Li, C., & Wang, L.-X. (2011) · Journal of the American Chemical Society · doi:10.1021/ja208390n · Cited by 166
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.
Natsume, A., Niwa, R., & Satoh, M. (2009) · PubMed Central · Cited by 165
Self-citationNavid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4423 · Cited by 165
“18K322A is produced in a YB2/0 rat myeloma cell line that has decreased fucosylation activity, potentially resulting in increased antibody-dependent cellular cytotoxicity (ADCC).(7,8) In vitro analyses have shown that hu14.”
BackgroundRecombinant therapeutic proteins: Production platforms and challenges
Dingermann, T. (2008) · Biotechnology Journal · doi:10.1002/biot.200700214 · Cited by 162
Malphettes, L., Freyvert, Y., Chang, J., Liu, P., Chan, E., Miller, J. C., Zhou, Z., Nguyen, T., Tsai, C., Snowden, A. W., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22751 · Cited by 164
“Compared to the fucose-containing version, a nonfucosylated carbohydrate chain attached to Fc at Asn297 greatly improves binding to FcgRIII (Shields et al., 2002) and increases in vitro ADCC activity 100-fold (Niwa et al., 2004; Shields et al., 2002; Shinkawa et al., 2003).”
BackgroundThe role of glycosylation in IBD
Theodoratou, E., Campbell, H., Ventham, N. T., Kolarich, D., Pučić-Baković, M., Zoldoš, V., Fernandes, D., Pemberton, I. K., Rudan, I., Kennedy, N. A., et al. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.78 · Cited by 162
Fc-Glycosylation of IgG1 is Modulated by B-cell Stimuli
Wang, J., Balog, C. I. A., Stavenhagen, K., Koeleman, C. A. M., Scherer, H. U., Selman, M. H. J., Deelder, A. M., Huizinga, T. W. J., Toes, R. E. M., & Wuhrer, M. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.004655 · Cited by 162
Engineering of glycosylation in yeast and other fungi: current state and perspectives
De Pourcq, K., De Schutter, K., & Callewaert, N. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2721-1 · Cited by 160
“These are the type of glycans found on the Fc part of human IgG, where this particular non-fucosylated structure has great advantages over the naturally occurring core-fucosylated counterpart: it increases the potential of the antibody for antibody-dependent cytotoxicity, which is desirable in many anti-tumor and anti…”
BackgroundFUT8 Alpha-(1,6)-Fucosyltransferase in Cancer
Bastian, K., Scott, E., Elliott, D. J., & Munkley, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010455 · Cited by 160
“Antibody-Dependent Cellular Cytotoxicity (ADCC) ADCC is a lytic attack on antibody-targeted cells that is elicited upon binding of lymphocyte receptors (FcRs) to the constant region (Fc) of antibodies [99].”
BackgroundRevisiting the Role of Glycosylation in the Structure of Human IgG Fc
Borrok, M. J., Jung, S. T., Kang, T. H., Monzingo, A. F., & Georgiou, G. (2012) · ACS Chemical Biology · doi:10.1021/cb300130k · Cited by 158
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 157
“YB2/0 Rat hybridoma (B lymphoblast) Low natural FUT8 expression levels (127, 134, 154)”
BackgroundFucosylation Is a Promising Target for Cancer Diagnosis and Therapy
Miyoshi, E., Moriwaki, K., Terao, N., Tan, C.-C., Terao, M., Nakagawa, T., Matsumoto, H., Shinzaki, S., & Kamada, Y. (2012) · Biomolecules · doi:10.3390/biom2010034 · Cited by 164
“Lack of IgG core fucosylation results in 50–100 times higher activity of antibody-dependent cellular cytotoxicity [15].”
BackgroundIshida, T., Iida, S., Akatsuka, Y., Ishii, T., Miyazaki, M., Komatsu, H., Inagaki, H., Okada, N., Fujita, T., Shitara, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0983 · Cited by 161
“affinity to Fc R on effector cells (15, 16).”
BackgroundSelf-citationImai-Nishiya (2007) · doi:10.1186/1472-6750-7-84 · Cited by 157
“This finding enabled us to design a new conversion strategy for the manufacture of next-generation therapeutic antibodies fully lacking core fucosylation and with enhanced ADCC.”
BackgroundMethodInfluentialClinical Cancer Therapy by NK Cells via Antibody‐Dependent Cell‐Mediated Cytotoxicity
Alderson, K. L., & Sondel, P. M. (2011) · BioMed Research International · doi:10.1155/2011/379123 · Cited by 156
Changes in IgG and total plasma protein glycomes in acute systemic inflammation
Novokmet, M., Lukić, E., Vučković, F., Đurić, Ž., Keser, T., Rajšl, K., Remondini, D., Castellani, G., Gašparović, H., Gornik, O., et al. (2014) · Scientific Reports · doi:10.1038/srep04347 · Cited by 172
Site-Specific Glycan-Peptide Analysis for Determination of N-Glycoproteome Heterogeneity
Parker, B. L., Thaysen‐Andersen, M., Solis, N., Scott, N. E., Larsen, M. R., Graham, M. E., Packer, N. H., & Cordwell, S. J. (2013) · Journal of Proteome Research · doi:10.1021/pr400783j · Cited by 159
Production technologies for monoclonal antibodies and their fragments
Andersen, D. C., & Reilly, D. E. (2004) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2004.08.002 · Cited by 183
Enzymes for N-Glycan Branching and Their Genetic and Nongenetic Regulation in Cancer
Kizuka, Y., & Taniguchi, N. (2016) · Biomolecules · doi:10.3390/biom6020025 · Cited by 178
“The removal of core fucose from IgG-Fc N-glycans was found to enchance ADCC activity by approximately 50-fold [116,117].”
BackgroundGlycosylation: impact, control and improvement during therapeutic protein production
Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J. (2014) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.793649 · Cited by 155
“…of a knockout CHO cell line that produces completely defucosylated mAbs (Natsume et al., 2009; Yamane-Ohnuki et al., 2004), which exhibit enhanced ADCC (Masuda et al., 2007; Satoh et al., 2006) and achieve therapeutic efficacy at low doses (Shinkawa et al., 2003; Yamane-Ohnuki et al., 2004).”
BackgroundInfluentialNimmerjahn, F., & Ravetch, J. V. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_86 · Cited by 180
Engineered therapeutic antibodies with improved effector functions
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 168
Self-citationThe Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 172
The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease
Russell, A. C., Šimurina, M., Garcia, M., Novokmet, M., Wang, Y., Rudan, I., Campbell, H. J., Lauc, G., Thomas, M. G., & Wang, W. (2017) · Glycobiology · doi:10.1093/glycob/cwx022 · Cited by 161
Fcγ receptor pathways during active and passive immunization
Bournazos, S., & Ravetch, J. V. (2015) · Immunological Reviews · doi:10.1111/imr.12343 · Cited by 146
“For example, the presence of a branching fucose has been shown to reduce affinity specifically for the activating type I FccR, FccRIIIa, without any impact on the capacity of the Fc domain to interact with other classes of type I FccRs (23, 24).”
BackgroundN-Glycosylation and Inflammation; the Not-So-Sweet Relation
Radovani, B., & Gudelj, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.893365 · Cited by 162
Chapter 11 Selecting an Appropriate Method for Expressing a Recombinant Protein
Brondyk, W. H. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)63011-1 · Cited by 215
Herter, S., Birk, M. C., Klein, C., Gerdes, C., Umana, P., & Bacac, M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301249 · Cited by 143
Glycosylation Changes in Brain Cancer
Veillon, L., Fakih, C., Abou-El-Hassan, H., Kobeissy, F., & Mechref, Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00271 · Cited by 140
Pelaia, C., Calabrese, C., Vatrella, A., Busceti, M. T., Garofalo, E., Lombardo, N., Terracciano, R., & Pelaia, G. (2018) · BioMed Research International · doi:10.1155/2018/4839230 · Cited by 146
“Besides linking IL-5Rα through its Fab regions, benralizumab also binds via the constant Fc fragment to the FcγRIIIa receptor, located on cell membrane of natural killer (NK) cells (Figure 2) [60, 61].”
BackgroundCrystal structure of mammalian α1,6-fucosyltransferase, FUT8
Ihara, H., Ikeda, Y., Toma, S., Wang, X., Suzuki, T., Gu, J., Miyoshi, E., Tsukihara, T., Honke, K., Matsumoto, A., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl079 · Cited by 140
“Moreover, the core fucosylation of N-glycans in human immunoglobulin (Ig) G1 was found to regulate antibody-dependent cellular cytotoxicity (ADCC) (Shields et al. 2002; Shinkawa et al. 2003).”
BackgroundFcγ Receptor Heterogeneity in Leukocyte Functional Responses
Rosales, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00280 · Cited by 161
“Together with the increased receptor binding, these IgG antibodies also augmented ADCC activity against various tumor cells (119, 132, 133).”
Backgrounddel Val, I. J., Kontoravdi, C., & Nagy, J. M. (2010) · Biotechnology Progress · doi:10.1002/btpr.470 · Cited by 139
“However, it was later observed that the addition of bisecting GlcNAc residues increased ADCC by competing with the addition of fucose to the oligosaccharide structures.(54) Additional Figure 2.”
BackgroundThe role and function of Fcγ receptors on myeloid cells
Bournazos, S., Wang, T. T., & Ravetch, J. V. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0045-2016 · Cited by 138
“For example, the branching fucose residue regulates the Fc domain affinity specifically for the activating type I FcγR, FcγRIIIa, without any impact on the capacity of the Fc domain to interact with other classes of type I FcγRs (20, 21).”
BackgroundBoune, S., Hu, P., Epstein, A. L., & Khawli, L. A. (2020) · Antibodies · doi:10.3390/antib9020022 · Cited by 156
Irvine, E. B., & Alter, G. (2020) · Glycobiology · doi:10.1093/glycob/cwaa018 · Cited by 151
Deletion of Core Fucosylation on α3β1 Integrin Down-regulates Its Functions
Zhao, Y., Itoh, S., Wang, X., Isaji, T., Miyoshi, E., Kariya, Y., Miyazaki, K., Kawasaki, N., Taniguchi, N., & Gu, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608764200 · Cited by 139
Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential
Cymer, F., Beck, H., Rohde, A., & Reusch, D. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.11.001 · Cited by 160
Glycoengineering of Antibodies for Modulating Functions
Wang, L., Tong, X., Li, C., Giddens, J. P., & Li, T. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012911 · Cited by 148
“In addition to mammalian cell line glycoengineering, nonmammalian cell lines, including yeast (31), insect (60, 61), fungi (62) and plant (29, 63, 64), that lack endogenous FUT8 activity were also explored for the production of nonfucosylated antibodies.”
BackgroundInfluentialRole of Fcγ receptors in HER2-targeted breast cancer therapy
Musolino, A., Gradishar, W. J., Rugo, H. S., Nordstrom, J. L., Rock, E. P., Arnaldez, F. I., & Pegram, M. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003171 · Cited by 156
Function and 3D Structure of the N-Glycans on Glycoproteins
Nagae, M., & Yamaguchi, Y. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13078398 · Cited by 134
“effector functions of therapeutic antibodies [26,27].”
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Navid, F., M. Santana, V., & C. Barfield, R. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054167 · Cited by 135
Engineering mammalian cells in bioprocessing – current achievements and future perspectives
Lim, Y., Wong, N. S. C., Lee, Y. Y., Ku, S. C. Y., Wong, D. C. F., & Yap, M. G. S. (2010) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090363 · Cited by 133
Understanding the Chemistry and Biology of Glycosylation with Glycan Synthesis
Krasnova, L., & Wong, C.-H. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034420 · Cited by 133
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective
Desjarlais, J. R., Lazar, G. A., Zhukovsky, E. A., & Chu, S. Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.009 · Cited by 154
DiLillo, D. J., & Ravetch, J. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0120 · Cited by 132
“For example, afucosylated IgG demonstrates enhanced affinity specifically for huFcgRIIIA, thereby increasing the A:I ratio and resulting in increased ADCC/ADCP effector function both in vitro and in vivo (24).”
BackgroundImpact of Glycosylation on Effector Functions of Therapeutic IgG
Abès, R., & Teillaud, J. (2010) · Pharmaceuticals · doi:10.3390/ph3010146 · Cited by 156
“Hypergalactosylation positively impacts ADCC mediated by FcγRIIIA (CD16), but does dot modify the ability of IgG to form rosettes with cells expressing the high-affinity activating FcγRI [13].”
BackgroundInfluentialGornik, O., Štambuk, T., & Lauc, G. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.12.004 · Cited by 162
“Small fraction of IgG which lack core-fucose are over 100 times more effective in initiating ADCC through binding to FcγRIIIa and this seems to be the primary mode of function of therapeutic anti-cancer monoclonal antibodies [32,36,37].”
BackgroundIgG Glycome in Colorectal Cancer
Vučković, F., Τheodoratou, E., Thaçi, K., Timofeeva, M. N., Vojta, A., Štambuk, J., Pučić‐Baković, M., Rudd, P. M., Đerek, L., Servis, D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1867 · Cited by 142
Beck, A., Bussat, M., Zorn, N., Robillard, V., Klinguer, C., Chenu, S., Goetsch, L., Corvaïa, N., DORSSELAER, A. V., & Haeuw, J. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.06.052 · Cited by 147
Innate immune mediators in cancer: between defense and resistance
Berraondo, P., Minute, L., Ajona, D., Corrales, L. P., Melero, I., & Pío, R. (2016) · Immunological Reviews · doi:10.1111/imr.12464 · Cited by 147
Engineering antibodies for clinical applications
Jain, M., Kamal, N., & Batra, S. K. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.05.001 · Cited by 151
Harvey, D. J. (2008) · Mass Spectrometry Reviews · doi:10.1002/mas.20192 · Cited by 137
“(Hoshi, et al., 2004) IgG ( (Sriraman, et al., 2004) IgG 1 (Human) Rat hybridoma or CHO Hydrazine MALDI, HPLC, Glycans (2-AP), Absence of fucose but not presence of galactose or bisect enhances cellular toxicity (Shinkawa, et al., 2003) IgG 3 M o u s e Hydrazine, PNGase F R-TOF (+ve) (DHB), ESI, MS/MS, Glycans Effect…”
BackgroundOptimization of Protein Expression in Mammalian Cells
Hunter, M., Yuan, P., Vavilala, D. T., & Fox, M. (2018) · Current Protocols in Protein Science · doi:10.1002/cpps.77 · Cited by 152
Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies
Beck, A., & Liu, H. (2019) · Antibodies · doi:10.3390/antib8010018 · Cited by 138
“Because the absence of the core-fucose can result in enhanced ADCC [122,129], the level of core-fucose has attracted great attention for the development of mAb therapeutics, especially to establish comparability or biosimilarity.”
BackgroundInfluential
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.